These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27088632)

  • 1. Treatment of Helicobacter pylori infection: Where are we now?
    Liou JM; Wu MS; Lin JT
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1918-1926. PubMed ID: 27088632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 3. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.
    Miftahussurur M; Yamaoka Y
    Molecules; 2015 Apr; 20(4):6068-92. PubMed ID: 25856059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori eradication in West Asia: a review.
    Fakheri H; Bari Z; Aarabi M; Malekzadeh R
    World J Gastroenterol; 2014 Aug; 20(30):10355-67. PubMed ID: 25132752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
    Dos Santos AA; Carvalho AA
    World J Gastroenterol; 2015 Jan; 21(1):139-54. PubMed ID: 25574087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
    Papastergiou V; Georgopoulos SD; Karatapanis S
    World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.
    Georgopoulos SD; Papastergiou V; Karatapanis S
    Expert Opin Pharmacother; 2015; 16(15):2307-17. PubMed ID: 26330278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Helicobacter pylori infection 2016.
    O'Connor A; Fischbach W; Gisbert JP; O'Morain C
    Helicobacter; 2016 Sep; 21 Suppl 1():55-61. PubMed ID: 27531541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward population specific and personalized treatment of Helicobacter pylori infection.
    Liou JM; Chen PY; Kuo YT; Wu MS;
    J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori.
    Malfertheiner P; Selgrad M
    Curr Opin Gastroenterol; 2014 Nov; 30(6):589-95. PubMed ID: 25268839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
    Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
    Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
    Marin AC; McNicholl AG; Gisbert JP
    Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Aspects in Choosing a Helicobacter pylori Therapy.
    Molina-Infante J; Shiotani A
    Gastroenterol Clin North Am; 2015 Sep; 44(3):519-35. PubMed ID: 26314666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.
    Kawai T; Yamagishi T; Yagi K; Kataoka M; Kawakami K; Sofuni A; Itoi T; Sakai Y; Moriyasu F; Osaka Y; Takagi Y; Aoki T; Rimbara E; Noguchi N; Sasatsu M
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S171-4. PubMed ID: 19120893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.